Physician profile

Abigail Ettinger

Pediatrics · Raritan, NJ

NPI 1871924670

$655.28

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$210.12

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $226.14 2019-2024 Bexsero
Sanofi Pasteur INC. $172.99 2022-2024
Cognoa, INC. $76.17 2022
Pfizer INC. $58.10 2021-2023
Merck Sharp & Dohme LLC $40.63 2023 Vaxneuvance, Gardasil 9, Vaxelis
Takeda Pharmaceuticals U.S.A., INC. $40.58 2020-2023 Vpriv
Ultragenyx Pharmaceutical INC. $22.81 2022
Genzyme Corporation $17.86 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Abigail Ettinger

$655.28

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/1385985/abigail-ettinger

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.